Search research articles
Contact Us
Filters
Showing results (11-20 of 46) with videos related to
Page
of 5
Sort By:
Journal of Separation Science
|
October 18, 2016
First separation of four aromatic acids and two analogues with similar structures and polarities from Clematis akebioides by high-speed counter-current chromatography
Chengcheng Gong, Tao Chen, Huifeng Chen, et al.
Scientific Reports
|
September 29, 2018
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
Yannan Zhao, Cheng Liu, Yingjian Zhang, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 19, 2025
<sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival
Yizhao Xie, Yifan Chen, Cheng Liu, et al.
Epigenetics & Chromatin
|
September 5, 2020
DNA methylation suppresses chitin degradation and promotes the wing development by inhibiting Bmara-mediated chitinase expression in the silkworm, Bombyx mori
Guanfeng Xu, Yangqin Yi, Hao Lyu, et al.
Therapeutic Advances in Medical Oncology
|
June 28, 2021
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer
Yi Li, Wei Li, Chengcheng Gong, et al.
The Oncologist
|
July 25, 2019
<sup>18</sup>F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with <sup>18</sup>F-FDG PET/CT
Cheng Liu, Chengcheng Gong, Shuai Liu, et al.
Therapeutic Advances in Medical Oncology
|
September 3, 2025
Efficacy and safety of utidelone in pretreated patients with metastatic breast cancer in China: a multicenter, real-world study
Shihui Hu, Tengfei Chao, Ning Xie, et al.
Cancer Medicine
|
October 6, 2020
Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer
Yannan Zhao, Yi Li, Chengcheng Gong, et al.
Therapeutic Advances in Drug Safety
|
December 30, 2022
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data
Chengcheng Gong, Yizhao Xie, Yannan Zhao, et al.
Cancer Medicine
|
March 11, 2022
Heterogeneity derived from <sup>18</sup> F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients
Yizhao Xie, Cheng Liu, Yannan Zhao, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 46) with videos related to
Sort By:
Page
of 5
Journal of Separation Science
|
October 18, 2016
First separation of four aromatic acids and two analogues with similar structures and polarities from Clematis akebioides by high-speed counter-current chromatography
Chengcheng Gong, Tao Chen, Huifeng Chen, et al.
Scientific Reports
|
September 29, 2018
Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
Yannan Zhao, Cheng Liu, Yingjian Zhang, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 19, 2025
<sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival
Yizhao Xie, Yifan Chen, Cheng Liu, et al.
Epigenetics & Chromatin
|
September 5, 2020
DNA methylation suppresses chitin degradation and promotes the wing development by inhibiting Bmara-mediated chitinase expression in the silkworm, Bombyx mori
Guanfeng Xu, Yangqin Yi, Hao Lyu, et al.
Therapeutic Advances in Medical Oncology
|
June 28, 2021
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer
Yi Li, Wei Li, Chengcheng Gong, et al.
The Oncologist
|
July 25, 2019
<sup>18</sup>F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with <sup>18</sup>F-FDG PET/CT
Cheng Liu, Chengcheng Gong, Shuai Liu, et al.
Therapeutic Advances in Medical Oncology
|
September 3, 2025
Efficacy and safety of utidelone in pretreated patients with metastatic breast cancer in China: a multicenter, real-world study
Shihui Hu, Tengfei Chao, Ning Xie, et al.
Cancer Medicine
|
October 6, 2020
Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer
Yannan Zhao, Yi Li, Chengcheng Gong, et al.
Therapeutic Advances in Drug Safety
|
December 30, 2022
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data
Chengcheng Gong, Yizhao Xie, Yannan Zhao, et al.
Cancer Medicine
|
March 11, 2022
Heterogeneity derived from <sup>18</sup> F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients
Yizhao Xie, Cheng Liu, Yannan Zhao, et al.
Page
of 5